Inceptionr LLC Sells 2,628 Shares of Biogen Inc. $BIIB

Inceptionr LLC lowered its holdings in shares of Biogen Inc. (NASDAQ:BIIB) by 53.9% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,248 shares of the biotechnology company’s stock after selling 2,628 shares during the quarter. Inceptionr LLC’s holdings in Biogen were worth $412,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Reflection Asset Management acquired a new stake in Biogen during the 4th quarter worth approximately $25,000. WPG Advisers LLC boosted its holdings in shares of Biogen by 417.9% in the fourth quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company’s stock valued at $26,000 after buying an additional 117 shares during the period. First Horizon Corp bought a new stake in shares of Biogen during the fourth quarter worth $30,000. WFA of San Diego LLC acquired a new stake in shares of Biogen during the second quarter worth $32,000. Finally, Root Financial Partners LLC raised its holdings in shares of Biogen by 198.4% during the fourth quarter. Root Financial Partners LLC now owns 185 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 123 shares during the period. Institutional investors own 87.93% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently commented on BIIB shares. HC Wainwright restated a “buy” rating on shares of Biogen in a report on Thursday, May 14th. Zacks Research lowered Biogen from a “hold” rating to a “strong sell” rating in a research report on Monday, June 29th. Guggenheim boosted their target price on Biogen from $260.00 to $280.00 and gave the company a “buy” rating in a research note on Tuesday, July 21st. Bank of America reduced their price target on Biogen from $217.00 to $215.00 and set a “neutral” rating for the company in a research report on Tuesday, July 21st. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Biogen in a report on Monday, June 22nd. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating, twelve have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $220.57.

Biogen Stock Performance

Shares of Biogen stock opened at $202.19 on Monday. Biogen Inc. has a 12-month low of $124.56 and a 12-month high of $219.72. The stock has a market cap of $29.85 billion, a P/E ratio of 21.69 and a beta of 0.16. The company has a quick ratio of 2.41, a current ratio of 3.06 and a debt-to-equity ratio of 0.34. The business’s 50 day moving average is $199.78 and its 200-day moving average is $189.95.

Biogen (NASDAQ:BIIB) last released its earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share for the quarter, beating the consensus estimate of $2.95 by $0.62. Biogen had a net margin of 13.81% and a return on equity of 12.83%. The business had revenue of $2.48 billion during the quarter, compared to analysts’ expectations of $2.29 billion. During the same period last year, the business earned $3.02 earnings per share. The firm’s revenue was up 1.9% on a year-over-year basis. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. Equities research analysts predict that Biogen Inc. will post 11.29 earnings per share for the current fiscal year.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.